secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001000694-23-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax President of R&D Gregory Glenn retiring March 31, signs consulting agreement through Dec 2024
--------------------------------------------------------------------------------

- Dr. Gregory Glenn steps down as President, R&D effective March 31, 2023.
- Consulting agreement provides $25k/month for first 12 months, then $12.5k/month through Dec 31, 2024.
- Equity awards continue to vest during consulting period; non-competition covenants begin post-retirement.
- He will serve as Strategic Research & Development Advisor after retirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/0001000694-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/nvax-20230320.htm
  HTML page:      https://secwatch.observer/filing/0001000694-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer